ACADIA pharmaceuticals Inc. (Nasdaq:Acad) stock is falling today on an article about drug Nuplazid.
Nuplazid is a drug that was approved by the U.S. food and drug administration (FDA) began to be sold to customers in June 2016. The drug was given accelerated approval by the FDA despite concerns that it might not help those suffering from Parkinson’s disease.
Now that two years have passed since the release of the ACADIA pharmaceuticals Inc.’s Nuplazid, some believe that the statement is not worth the risk. According to the Institute for safe medication practices, there were 244 deaths reported in the FDA adverse event reporting in November.
Now these figures had risen to 700 deaths and ACADIA pharmaceuticals Inc.’s Nuplazid is listed as a suspect in at least 500 of these reports. These figures have some health officials are concerned about the safety of the drug.
“It’s almost unheard of to have so many deaths,” Diana Zuckerman, President National research center of health, told CNN. “You just don’t see it in most of the new drugs — You don’t see all these reports so you should take this seriously.”
ACADIA pharmaceuticals Inc. without taking these requirements sitting. The company claims that the mortality rate for patients on the drug 12.4/100 per year. It is not as high as the mortality rate of 28.2/100 per year for patients with Parkinson’s disease. The company also says data do not show that his Medication was responsible for the deaths.
Shares of Acadia was below 25% as of Monday Afternoon.
At the time of this writing, William white not to take a position in any of the above securities.